Literature DB >> 31967022

CLINICALLY SILENT ADRENOCORTICOTROPIC HORMONE-SECRETING CROOKE CELL ADENOMA PRESENTING AS UNILATERAL EAR PAIN.

Krish J Khatri, Pedram Javanmard, Puneet S Pawha, Joshua D Miller.   

Abstract

OBJECTIVE: Crooke cell adenoma (CCA) is a rare tumor of the anterior pituitary. It is highly aggressive and carries significant risk of morbidity and mortality.
METHODS: This report focuses on the presentation of this disease process and review diagnosis and treatment. The patient is a 64-year-old male with a history of resected pituitary adenoma of unknown pathology.
RESULTS: The patient underwent serial magnetic resonance imaging surveillance for numerous years without recurrence of tumor, however eventually developed symptoms of worsening left ear pain over 3 weeks that rapidly evolved to include ptosis. Imaging revealed a new pituitary macroadenoma. Urgent surgical resection revealed histopathological diagnosis of CCA. Corticotroph adenomas represent a rare subset of pituitary tumors. Clinically silent pituitary tumors demonstrate relatively higher rates of cavernous sinus invasion (30% versus 18%) and progression or recurrence (34% versus 6%) when compared to nonfunctioning adenomas. In CCA, only 65% of patients have clinical features of Cushing disease at presentation. Twenty-four-hour urinary free cortisol is discussed in the literature as a potential tool, where a value 4 times the upper limit of normal was predictive of higher risk of having Crooke cell changes. With a recurrence rate of up to 60%, multimodal treatment (surgery and radiation) is preferred.
CONCLUSION: This case highlights early detection and treatment as keys to reducing the risk of morbidity and mortality from CCA. Currently, there are limited tools for identifying patients who are high risk for developing Crooke cell changes. Treatment modalities classically include surgery and radiotherapy. Adjuvant and novel chemotherapies are being explored.
Copyright © 2019 AACE.

Entities:  

Year:  2018        PMID: 31967022      PMCID: PMC6873864          DOI: 10.4158/ACCR-2018-0347

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  8 in total

1.  Crooke's Changes In Cushing's Syndrome Depends on Degree of Hypercortisolism and Individual Susceptibility.

Authors:  Edward H Oldfield; Mary Lee Vance; Robert G Louis; Carrie L Pledger; John A Jane; Maria-Beatriz S Lopes
Journal:  J Clin Endocrinol Metab       Date:  2015-07-06       Impact factor: 5.958

2.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

Review 3.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

4.  Prognostic indicators in an aggressive pituitary Crooke's cell adenoma.

Authors:  K Kovacs; C C Diep; E Horvath; M Cusimano; H Smyth; C Coire M Lombardero; B W Scheithauer; R V Lloyd
Journal:  Can J Neurol Sci       Date:  2005-11       Impact factor: 2.104

5.  Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma.

Authors:  David H George; Bernd W Scheithauer; Kalman Kovacs; Eva Horvath; William F Young; Ricardo V Lloyd; Frederic B Meyer
Journal:  Am J Surg Pathol       Date:  2003-10       Impact factor: 6.394

6.  A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.

Authors:  Arman Jahangiri; Jeffrey R Wagner; Melike Pekmezci; Anne Hiniker; Edward F Chang; Sandeep Kunwar; Lewis Blevins; Manish K Aghi
Journal:  Neurosurgery       Date:  2013-07       Impact factor: 4.654

Review 7.  Progress in the Diagnosis and Classification of Pituitary Adenomas.

Authors:  Luis V Syro; Fabio Rotondo; Alex Ramirez; Antonio Di Ieva; Murat Aydin Sav; Lina M Restrepo; Carlos A Serna; Kalman Kovacs
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-12       Impact factor: 5.555

8.  Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide.

Authors:  Athina Asimakopoulou; Marinela Tzanela; Ageliki Koletti; George Kontogeorgos; Stylianos Tsagarakis
Journal:  Clin Case Rep       Date:  2013-12-09
  8 in total
  2 in total

1.  Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report.

Authors:  Nipun Lakshitha de Silva; Noel Somasundaram; Roshana Constantine; Himashi Kularatna
Journal:  BMC Endocr Disord       Date:  2021-05-01       Impact factor: 3.263

Review 2.  Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: Case series and literature review.

Authors:  Dimin Zhu; Zongming Wang; Tian Tian; Xinyi Wu; Dongsheng He; Yonghong Zhu; Dawei Liu; Haijun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.